REGISTER NOW

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect to chemotherapy treatment. It can cause symptoms that range from sensitivity to touch and numbness to neuropathic pain in hands and feet. CIPN is notoriously difficult to grade objectively and has mostly relied on a clinician- or patient-based rating that is subjective and poorly reproducible. Thus, considerable effort has been aimed at identifying objective biomarkers of CIPN. Neurofilament light chain (NFL) is a structural component of the neuronal cytoskeleton that is released into the blood during neurodegeneration. In this webcast, we will cover the utility of NFL as a preclinical and clinical biomarker of CIPN, with a particular focus on the cutting-edge technologies developed by Quanterix that enable highly sensitive detection of NFL. We will also discuss the current limitations and future perspectives on the use of NFL as a biomarker of CIPN.

Speaker

Tore B. Stage, PhD, MSc Pharm

Professor of Translational Pharmacology and Head of Research at Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark

Tore B. Stage is a Professor of Translational Pharmacology and Head of Research at Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark. Dr. Stage has spent a decade doing translational research within chemotherapy-induced peripheral neuropathy and published the first large-cohort study assessing neurofilament light chain as a biomarker of paclitaxel-induced peripheral neuropathy.

REGISTER NOW